ClinicalTrials.Veeva

Menu

International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial

A

Ankara University

Status

Unknown

Conditions

Patent Ductus Arteriosus

Treatments

Device: Echocardiography

Study type

Observational

Funder types

Other

Identifiers

NCT02910609
Ankara University (Other Grant/Funding Number)

Details and patient eligibility

About

The three options for the treatment of patent ductus arterioles (PDA) in preterm infants are conservative approach, pharmacological intervention and surgical ligation. There is not any randomized-controlled trial that demonstrates the superiority of these approaches in preterm infants.

Full description

Patent ductus arteriosus (PDA), of which incidence is inversely related to gestational age and birth weight, is one of the the most common conditions among preterm infants.

In recent years, the use of antenatal steroids, postnatal surfactant, noninvasive ventilation strategies and low oxygen saturation targets have affected the incidence of hemodynamically significant PDA (HSPDA). There is not any consensus about the best approach on the clinical management of PDA in preterm infants. Over past years, the management of HSPDA shifted to aggressive medical and surgical intervention from conservative treatment, but conservative treatment approach has been mainly concerned again nowadays.

Today, the three options for the treatment of PDA in preterm infants are conservative approach, pharmacological intervention and surgical ligation. There is not any randomized-controlled trial that demonstrates the superiority of these approaches in preterm infants. Many countries including developed countries only give recommendations, instead of publishing guidelines, on screening, timing of treatment and treatment choices of PDA, because of the differences on management of PDA between the centers even within a single center.

Timing of PDA treatment and treatment choices at preterm infants born before 28 gestation weeks' differ in our country also in many countries over the world. In this study, it is aimed to record the managements of PDA detected beyond postnatal 3 days, to compare the effects of the managements at postnatal 3-7 days and after 7 days on closure, surgical ligation rates and side effects of drugs.

Enrollment

1,000 estimated patients

Sex

All

Ages

1 to 28 days old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Infants born at 24 0/7-28 6/7 gestation weeks'
  • PDA detected with ductal diameter equal or greater than 1.5 mm and LA/Ao equal or greater than 1.5 on echocardiography at or after postnatal 72 hours of life

Exclusion criteria

  • Infants died before 72 hours of life
  • Infants detected PDA but treated before 72 hours of life

Trial design

1,000 participants in 2 patient groups

Management at PN 3-7 days
Description:
Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated at 3-7 days of their life
Treatment:
Device: Echocardiography
Management after PN 7 days
Description:
Preterm infants with hemodynamically significant PDA confirmed by echocardiography and are treated beyond 7 days of their life
Treatment:
Device: Echocardiography

Trial contacts and locations

0

Loading...

Central trial contact

Emel Okulu, Attending; Ömer Erdeve, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems